National CRE News In Your Inbox.
Sign up for Connect emails to stay informed with CRE stories that are 150 words or less.

Sanofi Commits to Spending $20B in U.S. Through 2030
French pharmaceutical giant Sanofi said Wednesday it planned to invest at least $20 billion in the U.S. through 2030. The expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to U.S. manufacturing. Reuters reported that the announcement follows similar commitments from Roche, Johnson & Johnson and Novartis following President Trump’s call for more onshore pharmaceutical manufacturing.
“Sanofi’s 13,000 U.S.-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas,” said CEO Paul Hudson. “Our expected investments in the U.S. will be substantial and will help ensure the production of key medicines in the U.S.”
Sanofi said it would substantially increase spending in the U.S. on R&D to accelerate its science. The company also plans to expand its U.S. manufacturing capacity, both through direct investments in Sanofi sites and through partnerships with other domestic manufacturers, to help ensure the production of medicines in the U.S.
Photo courtesy of Sanofi.
- ◦Development